VVUS News 3.93 09/15/2014 10:18:51 Vivus Inc (VVUS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vivus Inc (VVUS) 3.93 $VVUS

2 New Diet Drugs Coming Soon?
George Budwell, The Motley Fool - Motley Fool - Sat Sep 13, 1:05PM CDT
America's love of "supersized" everything has helped fuel an out-of-control obesity problem that is having dire consequences on human health and the economy. For instance, the CDC estimates that the annual medical cost of obesity in the U.S., as of...

Business Highlights
By The Associated Press - AP - Thu Sep 11, 4:57PM CDT
___

FDA panel backs Novo Nordisk injection for obesity
AP - Thu Sep 11, 4:42PM CDT
WASHINGTON (AP) — Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity.

FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...

How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?
at The Street - Thu Sep 11, 3:10PM CDT
Shares of Orexigen Therapeutics (OREX) were down in afternoon trading Thursday despite the FDA's approval of the company's diet pill Contrave.

FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised
at The Street - Thu Sep 11, 12:23PM CDT
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.

Pharma Equities Technical Coverage - VIVUS, Auxilium Pharma, Depomed, Endo Intl., and Perrigo
PR Newswire - Wed Sep 10, 8:10AM CDT
On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32, down 0.31%, while the index has advanced 6.94% in the last three months. Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ: VVUS), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), Endo International PLC (NASDAQ: ENDP), and Perrigo Company PLC (NYSE: PRGO). Free research on these five companies can be accessed at:

Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 8:45AM CDT
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech index by a full...

Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.

3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....

VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.

VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.

Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.

VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.

Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.

VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.

Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.

VIVUS Reports Second Quarter 2014 Financial Results
Marketwire - Fri Aug 08, 5:25AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the second quarter ended June 30, 2014 and provided a business update.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 231

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 211

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 249

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 432

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

StorageVault Canada Inc. Declares Q4 Dividend for Stakeholders

Updated Category News Views 91

StorageVault Canada Inc. Declares Q4 Dividend Announcement In a recent announcement, StorageVault Canada Inc. (TSX: SVI) revealed a quarterly dividend of $0.002991 per common share. This dividend is set to be distributed on January 15, 2026, to all shareholders listed as of December 31, 2025, coinciding with the ex-dividend date also on December 31. This designation...

Continue Reading
Calm Tuesday for Major Cryptocurrencies: Insights and Updates

Updated Category News Views 165

Market Overview: Cryptocurrencies in Focus On a quieter Tuesday, major cryptocurrencies such as Bitcoin, Ethereum, and XRP are showing a notable degree of stability. Bitcoin is currently trading just below $87,000 as it contends with the influx of new altcoin spot ETFs entering the market. Key Price Movements As investors navigate the changing landscape, here are the...

Continue Reading
Current Legal Challenge for Sun Communities, Inc. Investors

Updated Category News Views 286

Understanding the Sun Communities, Inc. Class Action Recently, a significant alert regarding Sun Communities, Inc. has been brought to attention for its stockholders. A class action has been initiated against the company due to allegations of misleading investors about possible conflicts of interest. Sun Communities, Inc. (SUI), primarily recognized for its investments in...

Continue Reading
Seeking Justice: BHC Sierra Vista Hospital Faces Allegations

Updated Category News Views 368

Labor Law Violation Allegations Against BHC Sierra Vista Hospital BHC Sierra Vista Hospital, Inc. is currently facing serious allegations for failing to provide its employees with legally mandated meal and rest breaks during their shifts. This alleged neglect not only goes against the California Labor Code but also contributes to the unfortunate situation where employees...

Continue Reading
ZKH Group Limited Reports Q3 2025 Financial Performance Insights

Updated Category News Views 183

Overview of ZKH Group Limited's Financial Results ZKH Group Limited (NYSE: ZKH), a premier platform for maintenance, repair, and operations (MRO) procurement services, has announced its unaudited financial results for the third quarter of 2025. The company has shown resilience and adaptability amidst a challenging economic landscape, with significant operational...

Continue Reading